The risk of metabolic disorders in patients treated with asenapine or olanzapine: A study conducted on real-world data in Italy and Spain

Expert Opinion on Drug Safety

Volumn 13, Issue 9, 2014, Pages 1149-1154

  Maina, Giuseppe ^a   Ripellino, Claudio ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b Data Management and Health Economist Modeling CSD Medical Research Srl   (Italy)

Author keywords

Asenapine; Atypical antipsychotics; Diabetes; Dyslipidemia; Metabolic adverse events; Olanzapine; Real world data

Indexed keywords

ASENAPINE; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RETROSPECTIVE STUDY; RISK; SPAIN; COHORT ANALYSIS; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; MENTAL DISORDERS; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; ITALY; MALE; MENTAL DISORDERS; MIDDLE AGED; RETROSPECTIVE STUDIES; SPAIN;

EID: 84906220954     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.943732     Document Type: Article

References (17)

1. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21(11):911-36
2. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93
3. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3): 28-36
4. Baker RA, Pikalov A, Tran QV, et al. Atypical antipsychotic drugs and diabetes mellitus in the US food and drug administration adverse event database: a systematic bayesian signal detection analysis. Psychopharmacol Bull 2009;42(1):11-31
5. Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy 2007;27(1):27-35
6. Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006;67(7):1034-41
7. Centorrino F, Mark TL, Talamo A, et al. Health and economic burden of metabolic comorbidity among individuals with bipolar disorder. J Clin Psychopharmacol 2009;29(6):595-600
8. Briles JJ, Rosenberg DR, Brooks BA, et al. Review of the safety of secondgeneration antipsychotics: are they really "atypically" safe for youth and adults? Prim Care Companion CNS Disord 2012;14:3
9. Asenapine summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001177/WC500096895.pdf
10. Kemp DE, Zhao J, Cazorla P, et al. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry 2014;75(3):238-45
11. Agenzia Italiana del Farmaco. L'uso dei farmaci in Italia - Rapporto OsMed 2012. Osservatorio nazionale dell'impiego dei medicinali. 2012. Available from: http://www.agenziafarmaco.gov.it/it/content/luso-deifarmaci-italia- rapporto-osmed-2012
12. Dietlein G, Schröder-Bernhardi D. Use of the mediplus patient database in healthcare research. Int J Clin Pharmacol Ther 2002;40(3):130-3
13. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51(8):480-91
14. Pendlebury J, Haddad P, Dursun S. Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol 2005;20(6):447-8
15. NICE. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (Update). National Clinical Guideline 82. NICE, London. 2009. Available from: http://tiny.cc/4nklh [Accessed on 20 September 10]
16. De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-24
17. Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005;19:102-9